[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-441651-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-441651-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","erratum-erratum-to-synergistic-efficacy-of-homoharringtonine-and-venetoclax-on-acute-myeloid-leukemia-cells-and-the-underlying-mechanisms","Erratum - Erratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms","","Erratum addresses an error in Figure 8A of the original article “Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms” (doi: 10.21037/atm-22-1459). The images showing tumorigenesis of AML xenograft mice treated with venetoclax and HHT alone or in combination were misused. Corrected Figure 8A is provided with the right panels and the proper version of Figure 8. Authors confirm the mistake does not significantly affect results or conclusions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/erratum-erratum-to-synergistic-efficacy-of-homoharringtonine-and-venetoclax-on-acute-myeloid-leukemia-cells-and-the-underlying-mechanisms/441651/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/erratum-erratum-to-synergistic-efficacy-of-homoharringtonine-and-venetoclax-on-acute-myeloid-leukemia-cells-and-the-underlying-mechanisms/441651.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What error is corrected in this erratum?","Question",{"text":63,"@type":64},"The erratum corrects an error in Figure 8A of the original article, where images representing tumorigenesis of AML xenograft mice were misused.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatment groups are shown in the corrected Figure 8A?",{"text":68,"@type":64},"Figure 8A includes groups treated with control, venetoclax, HHT, and the combination, across multiple time points (Day 0, Day 4, Day 7, Day 10).",{"name":70,"@type":61,"acceptedAnswer":71},"Does the corrected figure change the study’s overall conclusions?",{"text":72,"@type":64},"The authors confirmed the error does not significantly affect either the results or the conclusions of the paper.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},441651,1790790964,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":124,"preview_page_count":4},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Erratum  \nErratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms  \nEditorial Office  \nAnnals of Translational Medicine  \n[Correspondence to:](Correspondence to: Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org)[ Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org](Correspondence to: Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org).  \nSubmitted Sep 13, 2024. Accepted for publication Sep 19, 2024. Published online Nov 13, 2024.  \ndoi: 10.21037/atm-2024-32  \nView this article at: [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32)  \nErratum to: Ann Transl Med 2022;10:490 .  \nThe article (1) titled “Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms”(doi: 10.21037/atm-22-1459) unfortunately contains an error in Figure 8. In Figure 8A, the images representing the tumorigenesis of AML xenograft mice treated with venetoclax and HHT alone or in combination were misused.  \nFigure 8A of the original article:  \nDay 0  \nDay 4  \nDay 7  \nDay 10  \nControl Venetoclax HHT Combination  \n5.0  \n4.0  \n3.0 ×105 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×106 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×107 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×108 2.0  \n1.0  \n© AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32)  \nPage 2 of 4 Editorial Office. Erratum  \nFigure 8A after correction:  \nControl Venetoclax HHT Combination  \nDay 0  \nDay 4  \nDay 7  \nDay 10  \n5.0  \n4.0  \n3.0 ×105 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×106 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×107 2.0  \n1.0  \n5.0  \n4.0  \n3.0 ×108 2.0  \n1.0  \n© AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32)  \nAnnals of Translational Medicine, Vol 13, No 6 December 2025 Page 3 of 4  \nThe correct version of Figure 8 was shown below:  \nA  \nDay 0  \nDay 4  \nDay 7  \nDay 10  \nControl Venetoclax HHT Combination  \n5.0 4.0  \n3.0 ×105 2.0  \n1.0  \n5.0 4.0  \n3.0 ×106 2.0  \n1.0  \n5.0 4.0  \n3.0 ×107 2.0  \n1.0  \n5.0 4.0  \n3.0 ×108 2.0  \n1.0  \nB  \nBioluminescence intensity  \nC  \nD  \nLung  \nLiver  \nSpleen  \nLung  \nLiver  \nSpleen  \nControl Venetoclax HHT Combination  \nE  \nF  \nCount  \n150  \n100  \n50  \n0  \n100  \nControl Venetoclax HHT Combination  \nCD45 PerCP subset CD45 PerCP subset CD45 PerCP subset CD45 PerCP subset  \n34.4 24.2 3.05 0.30  \n101 102 103 104 100 101 102 103 104 100 101 102 103 104100 101 102 103 104  \n50  \n40  \n30  \n20  \n10  \n0  \nControl Venetoclax HHT Combination  \n**  \n**  \n**  \nhCD45+,%  \nG  \n24  \n22  \n20  \n18  \n16  \nWeight, g  \nControl Venetoclax  \n**  \nHHT  \nCombination  \n0 5 10  \nH ** **  \nSurvival,%  \n100  \n50  \n0  \nControl Venetoclax  \n*  \nHHT  \nCombination  \n* **  \n0 10 20 30  \nDays Days  \n© AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32)  \nPage 4 of 4 Editorial Office. Erratum  \nThe authors confirmed this error did not significantly affect either the results or the conclusions of the paper. Click here to view the updated version of the article.  \nOpen Access Statement: This is an Open Access article distributed in accordance with the Creative Commons AttributionNonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: [https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by-nc-nd/4.0/](licenses/by-nc-nd/4.0/.)[.](licenses/by-nc-nd/4.0/.)  \nReferences  \n1. Yuan F, Li D, Li G, et al. Synergistic efficacy of homoha","cbCaij3yV7X7mUgG","https://ap.wps.com/l/cbCaij3yV7X7mUgG","pdf",1771917,"English","# Erratum notice\n## Error description in Figure 8A\n## Corrected Figure 8 and confirmed impact\n## Publication and licensing information\n## Reference and citation","[{\"question\":\"What error is corrected in this erratum?\",\"answer\":\"The erratum corrects an error in Figure 8A of the original article, where images representing tumorigenesis of AML xenograft mice were misused.\"},{\"question\":\"Which treatment groups are shown in the corrected Figure 8A?\",\"answer\":\"Figure 8A includes groups treated with control, venetoclax, HHT, and the combination, across multiple time points (Day 0, Day 4, Day 7, Day 10).\"},{\"question\":\"Does the corrected figure change the study’s overall conclusions?\",\"answer\":\"The authors confirmed the error does not significantly affect either the results or the conclusions of the paper.\"}]","Erratum - Erratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms | PDF",1790696955]